GreenShield Ventures: Shaping the Future of Healthcare Innovation in Canada
TORONTO, May 7, 2025 /CNW/ - GreenShield proudly announces the launch of GreenShield Ventures – an innovation hub dedicated to developing new products and services to revolutionize health outcomes for all Canadians.
As Canada's only national non-profit health and benefits company, GreenShield is uniquely positioned to spearhead transformative innovation for the greater good. GreenShield Ventures will harness the ingenuity of its talented developers and intrapreneurs to incubate and build groundbreaking digital solutions in insurance, benefits administration, and healthcare delivery. These forward-thinking solutions will then be embedded and scaled within GreenShield+, Canada's leading integrated health and benefits platform, ensuring a seamless health and benefits experience as new products and services are added.
'GreenShield's non-profit social enterprise model – free from shareholder constraints – empowers us to uniquely prioritize the longer-term health and well-being of Canadians,' says Zahid Salman, President and CEO, GreenShield. 'By leveraging real data insights along with purpose-driven innovation, GreenShield Ventures aims to enhance care, expand access, and break down systemic barriers across Canada's health landscape, furthering our mission of Better Health for All.'
At the helm of GreenShield Ventures is Luke Vigeant, a visionary Canadian health entrepreneur and product design leader renowned for creating intuitive client experiences. Vigeant is the co-founder and former President of Inkblot Technologies – a mental health platform known for its personalized therapist matching tool and user-centric approach. Vigeant brought his expertise to GreenShield in 2021 when the company acquired Inkblot to become part of GreenShield Health. Vigeant's role was then expanded to oversee the development of a new integrated health and benefits ecosystem, later named GreenShield+. Since then, GreenShield Health has become Canada's fastest-growing digital healthcare providers, integrating mental health, telemedicine, pharmacy and chronic disease management services along with benefits coverage and claims reimbursement into the GreenShield+ ecosystem.
'True innovation begins with a deep understanding of patients and plan members,' says Luke Vigeant, Senior Vice President, GreenShield Ventures. 'GreenShield Ventures places Canadians at the heart of our innovation process – developing and testing solutions within our ecosystem to ensure they meet the evolving needs of those we serve. By validating and then seamlessly integrating our innovations into GreenShield+, we know we are delivering an unparalleled health and benefits experience.'
Founded in 1957 as a purpose-driven non-profit, GreenShield is committed to reinvesting its excess earnings to directly support the health and well-being of underserved communities. Through GreenShield Cares, the company has committed $75 million to improve the health of over one million Canadians by the end of this year, with a focus on mental health, essential medicines, and chronic disease management. United by a commitment to advancing health equity, GreenShield Ventures will work closely with GreenShield Cares to develop products and services that meet the needs of all Canadians.
To learn more about how GreenShield Ventures is leveraging purpose-driven innovation to advance Better Health for All visit GreenShield's website Purpose driven innovation | GreenShield Ventures .
About GreenShield
As Canada's only national non-profit health and benefits company, GreenShield believes health care is a right, not a privilege. We're dedicated to improving health outcomes, driving systemic change, and building a future where every Canadian can reach their full health and well-being potential.
We are revolutionizing the health and benefits experience with coverage and care in one place. Through our unique integrated payer-provider ('payvider') model, we offer insurance, administer benefits and pay claims as a 'payer' while offering health services such as mental health, pharmacy, telemedicine and chronic disease management as a 'provider'.
As a non-profit social enterprise without shareholders, we prioritize and reinvest our excess earnings to directly support underserved communities. Through GreenShield Cares, we've committed $75 million to improve the health of over one million Canadians by the end of 2025, focusing on mental health, essential medicines, and chronic disease management. Our scalable initiatives deliver meaningful change in pursuit of Better Health for All.
GreenShield is proud to be recognized as one of Canada's Most Admired Corporate Cultures, a leading Imagine Canada Caring Company, and named on the Fortune's Change the World list.
SOURCE GreenShield
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
RBC iShares (BlackRock) Opens the Market
Toronto, Ontario--(Newsfile Corp. - June 10, 2025) - Steven Leong, Head of Product, BlackRock Canada, and his team, joined Graham MacKenzie, Managing Director, Exchange Traded Products, Toronto Stock Exchange (TSX), to open the market and celebrate the launch of the new ETF: iShares Core Canadian Short-Mid Term Universe Bond Index ETF (TSX: XSMB). Cannot view this video? Visit: The iShares Core Canadian Short-Mid Term Universe Bond Index ETF will provide investors with exposure to a broadly diversified range of Canadian domiciled bonds with maturities between 1 and 10 years, which may include any or all of federal, provincial, corporate (including certain qualifying asset-backed securities) and municipal bonds. Canadians continue to embrace fixed income ETFs as efficient tools for building resilient, well-diversified portfolios. With this launch, we are excited to provide access to a broad portfolio of Canadian government and corporate bonds with 10 years remaining to maturity or less. This exposure allows investors to generate income while offering a source of portfolio stabilization amid volatility. MEDIA CONTACT:Sydney PunchardAssociate, Corporate To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Politico
42 minutes ago
- Politico
HHS justifies decision to stop recommending Covid shots during pregnancy with studies supporting the shots' safety
The Department of Health and Human Services is circulating a document on Capitol Hill to explain its decision to remove the Covid-19 vaccine recommendation for pregnant women — citing studies that largely found the shot is safe. The document, which HHS sent to lawmakers days before Secretary Robert F. Kennedy Jr. announced his plan to fire the panel that advises the CDC on immunizations, says that studies have shown that women who got the vaccine during pregnancy had higher rates of various complications. And it claims that 'a number of studies in pregnant women showed higher rates of fetal loss if vaccination was received before 20 weeks of pregnancy,' footnoting a research paper on vaccination during pregnancy. But Dr. Maria P. Velez of McGill University, the lead author of one of the studies, told POLITICO in an email that 'the results of our manuscript were misinterpreted.' The 2023 study shows a slightly higher rate of miscarriages among women who were immunized against Covid-19 during their pregnancies. But, Velez said, that after adjusting for 'variables that can confound a crude association,' like 'age, rurality, neighbourhood income quintile, immigration status, comorbidity' and other factors that could affect the outcome, Canadian researchers found 'no association between SARS-CoV-2 vaccination and an increased risk of miscarriage.' Raw numbers don't account for significant differences among the groups being compared — such as underlying conditions and when during pregnancy the people were vaccinated, said Katelyn Jetelina, an epidemiologist who's consulted for the Centers for Disease Control and Prevention. Scientists, including the Canadian researchers, use statistical methods to adjust for those factors, she said, which is how they determined the vaccine wasn't associated with miscarriage. In a statement, HHS spokesperson Andrew Nixon pointed to the raw study data, which showed a slightly higher rate of miscarriage in the first half of pregnancy for women who were vaccinated against Covid compared with those who weren't. 'The underlying data speaks for itself — and it raises legitimate safety concerns,' he said. 'HHS will not ignore that evidence or downplay early pregnancy loss.' Nixon added that HHS and the CDC encourage people to talk to their providers 'about any personal medical decision.' Vaccine researchers and obstetricians criticized the decision to remove the recommendation for pregnant women, and researchers cited in the HHS document largely dismissed any connection between Covid vaccination and miscarriages. 'Given that COVID-19 infection during pregnancy is associated with serious maternal and neonatal morbidity, the current study can inform healthcare providers, pregnant women and those considering a pregnancy about the safety of SARS-CoV-2 vaccination in relation to miscarriage risk,' Velez and her co-authors wrote in the study. That research was based on health-system data from Ontario, Canada, and aligned with similar population studies in the U.S., Scotland and Norway. Similarly, HHS cited an April 2022 study in its document concerning mRNA vaccination in people undergoing in-vitro fertilization, which also found no adverse effects on conception rates or on early pregnancy outcomes. 'Administration of COVID-19 mRNA vaccines was not associated with an adverse effect on stimulation or early pregnancy outcomes after IVF,' the New York City-based researchers at the Icahn School of Medicine at Mount Sinai and Mount Sinai West hospital wrote in the study. 'Our findings contribute to the growing body of evidence regarding the safety of COVID-19 vaccination in women who are trying to conceive.' The HHS document also includes an incorrect link for that study, instead leading to a different study — also cited in HHS' document — by Israeli researchers that found the vaccine 'appears to be safe during pregnancy,' with no increase in preterm labor or in newborns with low birth weight. That February 2022 study did note a possible increase in preterm birth rates for women vaccinated during the second trimester, and the authors suggested future investigations of outcomes based on the timing of immunization. HHS' assertion about significant risks to pregnant women 'contradicts the bulk of published studies,' said Dr. Paul Offit, an expert who has served as an outside adviser on vaccines to the FDA and the CDC. HHS deviated from past practice when it changed the Covid vaccine guidance last month, announcing the decision without the endorsement of an existing outside panel of expert advisers. Dr. Steven Fleischman, president of the American College of Obstetricians and Gynecologists, told POLITICO at the time that he was disappointed by HHS' decision, and pointed to data showing that newborns can benefit from maternal antibodies from the vaccine for protection from Covid. 'In fact, growing evidence shows just how much vaccination during pregnancy protects the infant after birth, with the vast majority of hospitalized infants less than 6 months of age — those who are not yet eligible for vaccination — born to unvaccinated mothers,' Fleischman said.
Yahoo
an hour ago
- Yahoo
Olymel to build state-of-the-art integrated plant in Trois-Rivières
BOUCHERVILLE, QC, June 10, 2025 /CNW/ - Olymel, the Canadian leader in the production, processing and distribution of pork and poultry meats, today announced the construction of a major expansion of its La Fernandière plant in Trois-Rivières, a major investment of $142 million that will allow Olymel to better serve its customers in Canada and abroad. The work will begin in the next few days, with the start of operations scheduled for spring 2026. The project objectives Olymel is pursuing several objectives with this project and significant gains are expected in the first year of operation. The plant, which essentially manufactures sausages at the present time, will expand production to include a wider range of pork and poultry products. It will also be converted into an integrated facility where products can be fully processed and packaged on site, thus reducing the transport of raw materials, better aligning processes, and strengthening the company's productivity. Finally, this new plant will considerably increase Olymel's production capacity at a time when the organization is aiming to strengthen the positioning of its products across Canada. "We're very proud to announce this major expansion of our Trois-Rivières plant. It's a big step forward for Olymel. Having this state-of-the-art plant will create new possibilities for expansion and significantly improve our efficiency, which is central to our company's performance. The project is perfectly aligned with our strategy of capitalizing on the creation of value-added products made with meat of superior quality that's produced by local farmers," declared Yanick Gervais, CEO of Olymel. A technological trailblazer in Quebec's agri-food industry Innovation will be at the core of the project, with new systems optimized by artificial intelligence. The connectivity of all the equipment and components will be used to ensure optimized operations management. The technologies include a unique industrial battery system, a continuous cooking line, completely autonomous operations (slicing, packaging, boxing and palletizing), and autonomous vehicles, all of which are points of innovation for the Canadian agri-food sector. The modernization of operations will result in more consistent production, to better meet the needs of our customers here and abroad. State-of-the-art equipment will allow the plant to utilize the latest packaging technology, for increased flexibility that fosters the use of eco-friendly solutions. By allying these technologies with our workers' expertise, we will maximize our operational efficiency while placing a premium on the knowledge and experience of our teams. Finally, the plant will serve as an innovation hub for new artificial intelligence solutions that Olymel can deploy elsewhere in its network, with the goal of increasing its productivity and optimizing its operations. A comprehensive approach to sustainable development In terms of occupational health and safety, the new ergonomic equipment will reduce the number of physically demanding tasks for employees, improve employee comfort at operating stations, and free up workers so that they can focus on tasks requiring more precision. Everything in the project was designed to optimize energy consumption, with measures that include heat recovery, net–zero water-based cooking, and a heat exchanger to recover heat from wastewater. On-site industrial batteries will be used to store energy and better manage the plant's power consumption when the grid is at peak demand. The ham cooking systems will utilize closed-circuit water management, which saves much more energy and water. In addition, a primary and secondary water treatment plant will be built on site, along with the necessary retention pond, to manage stormwater runoff. Finally, reduced greenhouse gas emissions from transportation and the improved management of natural gas, refrigerants, electricity, and residual materials will all result in environmental gains. A project that drives prosperity in the Mauricie region Locally, the plant will generate new economic opportunities, including the creation of some 50 direct jobs—bringing the total number of employees up to 400—and many indirect jobs. To help power Quebec's economy, the vast majority of building materials chosen will be made in Quebec. The contractor chosen for the construction work, Construction Bertrand Dionne, is from Drummondville, and the palletizing and boxing services will be designed by Premier Tech, a company from Rivière-du-Loup. Parallel to this project, and with a view to optimizing its operations and capturing the full benefit of the new plant, Olymel will permanently close its Anjou facility (140 employees) and its Cap-de-la-Madeleine facility (150 employees) in spring 2026. All personnel will be offered positions in neighbouring Olymel plants, particularly the newly built facility, which will be located a dozen kilometres from the Cap-de-la-Madeleine plant. About Olymel Olymel is Canada's leader in production, processing and distribution of pork and poultry meats. Its mission is to feed the world with passion and with products of the highest quality. The company has production and processing facilities in Quebec, Ontario, Alberta, Saskatchewan and New Brunswick, and employs over 12,000 people. It has annual sales of around $4.5 billion. The company markets its products mainly under the Olymel, Pinty's, La Fernandière, Lafleur and Flamingo brands. SOURCE Olymel l.p. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
